Engineering Insulin Analogues for Selective Binding to Insulin Receptor Isoforms
Author Information
Author(s): Glendorf Tine, Stidsen Carsten E., Norrman Mathias, Nishimura Erica, Sørensen Anders R., Kjeldsen Thomas
Primary Institution: Diabetes Research Unit, Novo Nordisk A/S, Maaloev, Denmark
Hypothesis
The study aims to investigate the importance of the C-terminus of the B chain in insulin receptor isoform binding to explore the possibility of engineering tissue-specific insulin analogues.
Conclusion
The study discovered a new class of insulin analogues with 2–4-fold differences in binding affinities for the A and B isoforms of the insulin receptor.
Supporting Evidence
- Insulin analogues with 2-fold differences in relative IR isoform affinity were discovered.
- Position B25 was identified as a key determinant for isoform selectivity.
- Combining mutations at positions B25 and B27 resulted in analogues with enhanced binding selectivity.
Takeaway
Scientists created new types of insulin that work better in the liver than in other parts of the body, which could help people with diabetes manage their blood sugar more effectively.
Methodology
The study used total amino acid scanning mutagenesis to create insulin analogue libraries and determined binding affinities through competition assays.
Potential Biases
All authors are employed by Novo Nordisk A/S, which may introduce bias in the study's findings.
Limitations
The study does not provide extensive in vivo data to confirm the clinical benefits of the engineered analogues.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website